LTR Pharma Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Operating Revenue	0.72	1.51	0.05	-	-
Other Revenue	-	-	-	-	0.01
Revenue	0.72	1.51	0.05	-	0.01
Revenue Growth	-52.01%	2978.25%	-	-	-
Cost of Revenue	6.69	2.79	3.51	-	-
Gross Profit	-5.97	-1.28	-3.46	-	0.01
Selling, General & Admin	4.65	3.63	2.01	0.59	0.68
Research & Development	-	-	-	0.82	0.35
Other Operating Expenses	0.29	0.4	0.17	0.03	-
Operating Expenses	8.02	4.83	3.48	1.44	1.03
Operating Income	-13.99	-6.11	-6.94	-1.44	-1.02
Interest Expense	-0	-0	-0	-0	-0
Interest & Investment Income	0.9	0.6	0	0	0
Earnings From Equity Investments	-1.04	-0.06	-	-	-
Currency Exchange Gain (Loss)	-0.03	-0.02	-0.01	-0.02	-0.01
Pretax Income	-14.16	-5.59	-6.95	-1.45	-1.03
Net Income	-14.16	-5.59	-6.95	-1.45	-1.03
Net Income to Common	-14.16	-5.59	-6.95	-1.45	-1.03
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	182	167	139	260	-
Shares Outstanding (Diluted)	182	167	139	260	-
Shares Change	8.54%	19.96%	-46.34%	-	-
EPS (Basic)	-0.08	-0.03	-0.05	-0.01	-
EPS (Diluted)	-0.08	-0.03	-0.05	-0.01	-
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Free Cash Flow	-10.85	-4.45	-5.09	-1.54	-0.57
Free Cash Flow Per Share	-0.06	-0.03	-0.04	-0.01	-
Gross Margin	-	-84.75%	-	-	100.00%
Operating Margin	-1932.77%	-404.86%	-14162.27%	-	-11195.03%
Profit Margin	-1956.57%	-370.83%	-14192.25%	-	-11314.40%
Free Cash Flow Margin	-1498.07%	-294.96%	-10396.58%	-	-6258.86%
EBITDA	-13.99	-6.1	-6.94	-	-
D&A For EBITDA	0.01	0	0	-	-
EBIT	-13.99	-6.11	-6.94	-1.44	-1.02
Revenue as Reported	1.62	2.1	0.05	-	-
Advertising Expenses	0.86	0.75	0.36	-	0